[go: up one dir, main page]

WO2010061208A3 - Combination comprising a quinazoline derivative and a taxane - Google Patents

Combination comprising a quinazoline derivative and a taxane Download PDF

Info

Publication number
WO2010061208A3
WO2010061208A3 PCT/GB2009/051471 GB2009051471W WO2010061208A3 WO 2010061208 A3 WO2010061208 A3 WO 2010061208A3 GB 2009051471 W GB2009051471 W GB 2009051471W WO 2010061208 A3 WO2010061208 A3 WO 2010061208A3
Authority
WO
WIPO (PCT)
Prior art keywords
taxane
combination
quinazoline derivative
quinazoline
methylcarbamoylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/051471
Other languages
French (fr)
Other versions
WO2010061208A2 (en
Inventor
Daniel Mark Hickinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2010061208A2 publication Critical patent/WO2010061208A2/en
Publication of WO2010061208A3 publication Critical patent/WO2010061208A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A combination, comprising 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[l-(N- methylcarbamoylmethyl)piperidin-4-yl ]oxy}quinazoline, or a pharmaceutically acceptable salt thereof, and a taxane is described.
PCT/GB2009/051471 2008-11-03 2009-11-02 Therapeutic treatment 555 Ceased WO2010061208A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11071008P 2008-11-03 2008-11-03
US61/110,710 2008-11-03

Publications (2)

Publication Number Publication Date
WO2010061208A2 WO2010061208A2 (en) 2010-06-03
WO2010061208A3 true WO2010061208A3 (en) 2010-11-04

Family

ID=41528555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/051471 Ceased WO2010061208A2 (en) 2008-11-03 2009-11-02 Therapeutic treatment 555

Country Status (1)

Country Link
WO (1) WO2010061208A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2964638T3 (en) 2013-03-06 2018-01-31 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
WO2003039551A1 (en) * 2001-11-08 2003-05-15 Astrazeneca Ab Combination therapy comprising zd6474 and a taxane
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2009138781A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
WO2003039551A1 (en) * 2001-11-08 2003-05-15 Astrazeneca Ab Combination therapy comprising zd6474 and a taxane
US20050043395A1 (en) * 2001-11-08 2005-02-24 Astrazeneca Ab Combination therapy comprising zd6474 and a taxane
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2009138781A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CIARDIELLO F ET AL: "Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer", BRITISH JOURNAL OF CANCER, vol. 94, no. 11, June 2006 (2006-06-01), pages 1604 - 1609, XP002591605, ISSN: 0007-0920 *
DI LEO ANGELO ET AL: "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 DEC 2008 LNKD- PUBMED:18955454, vol. 26, no. 34, 1 December 2008 (2008-12-01), pages 5544 - 5552, XP002591604, ISSN: 1527-7755 *
SHERI K DENNISON ET AL: "A phase II clinical trial of ZD1839 (Iressa(TM)) in combination with docetaxel as first-line treatment in patients with advanced breast cancer", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO LNKD- DOI:10.1007/S10637-007-9055-6, vol. 25, no. 6, 12 June 2007 (2007-06-12), pages 545 - 551, XP019526143, ISSN: 1573-0646 *
TAKABATAKE DAISUKE ET AL: "Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCMADR, MDA-MB-231)", INTERNATIONAL JOURNAL OF CANCER, vol. 120, no. 1, January 2007 (2007-01-01), pages 181 - 188, XP002591603, ISSN: 0020-7136 *
XUE CHENGSEN ET AL: "ErbB3-dependent motility and intravasation in breast cancer metastasis.", CANCER RESEARCH 1 FEB 2006 LNKD- PUBMED:16452197, vol. 66, no. 3, 1 February 2006 (2006-02-01), pages 1418 - 1426, XP002591606, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2010061208A2 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2008055037A3 (en) Infusion devices and methods
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2007135527A3 (en) Benzimidazolyl compounds
IL204814A0 (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
IL211713A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, production thereof and use as medicaments
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
ZA200805756B (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivative
ZA201008283B (en) Fumarate salt of 4-(3-chloro-2-fluoroanilino) -7-methoxy-6-{[1-(n-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline
GB0623012D0 (en) Diphyllin and other lignans as a medicament for V-ATPase mediated disease
AU2006256369A8 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2010061208A3 (en) Combination comprising a quinazoline derivative and a taxane
WO2010122340A8 (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline
WO2007144699A3 (en) Process for the preparation of alfuzosin
ZA200802640B (en) 4-(-4bromo-2-fluoroanilino) -6-methoxy-7- (1-methyl-piperidin-4-ylmethoxy) quinazoline momohydrate
EP1992349B8 (en) CGRP antagonists, their preparation and use as a medicament
HK1164285A (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin- 4-yl]oxy}quinazoline
HK1122554A (en) 4- (4-bromo-2-fluoroanilino)-6-methoxy-7- (1-methylpiperidin-4 -ylmethoxy) quinazoline monohydrate
HK1101679A (en) Needle tip protector
WO2008005955A8 (en) Synthesis of heterocyclic compounds
AU2006907103A0 (en) Needle tip
AU2004905374A0 (en) Phacoemulsification needle
HK1166067A (en) Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
HK1107925A (en) No port phacoemulsification needle sleeve
AU2006903963A0 (en) Easy / (ezy) hem threader

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748138

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09748138

Country of ref document: EP

Kind code of ref document: A2